A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.

Trial Details

NCT ID
NCT07221500
Phase
PHASE2
Sponsor
Nurix Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • NX-5948
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Diego, California, United States|32.71571,-117.16472
  • Denver, Colorado, United States|39.73915,-104.9847
  • Coral Gables, Florida, United States|25.72149,-80.26838

Key Eligibility Criteria

  • Age: ≥ 18 years
  • Confirmed relapsed/refractory CLL/SLL that meets iwCLL criteria for diagnosis and systemic treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Must have received a covalent BTK inhibitor (BTKi), a non-covalent BTKi, and a BCL-2 inhibitor either in separate lines of therapy or in combinatio…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →